lymphoma

lymphoma
Name	Lymphoma
Field	Hematology, Oncology, Immunology
Symptoms	Lymphadenopathy, fever, night sweats, weight loss
Complications	Immunodeficiency, organ compression, infections
Onset	Any age
Risks	Immunosuppression, viral infections, autoimmune diseases, chemical exposures
Diagnosis	Biopsy, histopathology, immunophenotyping, imaging
Treatment	Chemotherapy, radiotherapy, immunotherapy, stem cell transplantation
Frequency	Variable by subtype and region

lymphoma

Lymphoma is a group of malignancies arising from cells of the lymphatic system, presenting with heterogeneous clinical features and biologic behavior. It encompasses diseases that originate in lymphocytes and lymphoid tissues, often involving lymph nodes, spleen, bone marrow, and extranodal sites. Management and outcomes vary widely across subtypes, requiring integration of pathology, molecular diagnostics, and multidisciplinary care.

Overview

Lymphomas are broadly categorized by the dominant malignant cell type and clinical course, with major divisions recognized by organizations such as the World Health Organization, National Cancer Institute, American Society of Clinical Oncology, and other professional bodies. Historic classifications evolved through contributions from figures associated with St. Bartholomew's Hospital, Memorial Sloan Kettering Cancer Center, and the Mayo Clinic, and were refined during international consensus conferences including meetings convened by the International Lymphoma Study Group. Important milestones in lymphoma research have been associated with laboratories at institutions like Johns Hopkins Hospital and University of Oxford.

Classification and subtypes

Contemporary taxonomy follows schemes published by the World Health Organization and incorporates morphologic, immunophenotypic, genetic, and clinical features. Major categories include entities historically linked to the work at St. Jude Children's Research Hospital and adult-focused centers such as Massachusetts General Hospital: aggressive B‑cell neoplasms typified by subtypes described in case series from Stanford University Medical Center; indolent B‑cell neoplasms studied at M.D. Anderson Cancer Center; T‑cell and natural killer‑cell neoplasms characterized in cohorts from Peking University and Osaka University; and classic entities recognized in registries maintained by the European Society for Medical Oncology and the Japanese Lymphoma Study Group.

Well-known subtypes clinically emphasized in trials at centers like Dana‑Farber Cancer Institute include diffuse large B‑cell lymphoma, follicular lymphoma, mantle cell lymphoma, Burkitt lymphoma, peripheral T‑cell lymphoma, and Hodgkin lymphoma, each with distinct immunophenotypes elucidated by teams at Karolinska Institutet and Institut Gustave Roussy.

Signs and symptoms

Common presentations, documented in cohorts reported by institutions including University College London and Karolinska Universitetssjukhuset, encompass painless lymphadenopathy, B symptoms (fever, night sweats, weight loss), and systemic manifestations such as pruritus or fatigue. Extranodal involvement produces organ‑specific signs: mediastinal masses causing cough or superior vena cava syndrome described in case reports from Cleveland Clinic; gastrointestinal lesions presenting with obstruction noted in series from Seoul National University Hospital; and central nervous system involvement reported in analyses from Mayo Clinic and Royal Marsden Hospital.

Causes and pathophysiology

Etiologic associations have been identified through epidemiologic work by agencies like the Centers for Disease Control and Prevention and collaborative studies from the International Agency for Research on Cancer. Viral agents such as Epstein–Barr virus, Human T‑lymphotropic virus 1, and hepatitis viruses have been implicated in subtype‑specific oncogenesis observed in cohorts at University of Tokyo and Oslo University Hospital. Immunodeficiency states, including iatrogenic immunosuppression after transplantation managed at centers like Cleveland Clinic Foundation and congenital syndromes described by investigators at Great Ormond Street Hospital, increase risk. Genetic alterations and signaling pathway disruptions identified through research at Cold Spring Harbor Laboratory and Broad Institute underlie malignant transformation, involving recurrent chromosomal translocations, somatic mutations, and microenvironment interactions elucidated in studies from Fred Hutchinson Cancer Center.

Diagnosis

Definitive diagnosis relies on tissue biopsy with morphologic evaluation and immunophenotyping performed in specialized laboratories such as those at Mayo Clinic Laboratories and Johns Hopkins Hospital. Ancillary testing includes flow cytometry developed at institutions like Stanford University, cytogenetics and fluorescence in situ hybridization used in diagnostic programs at Memorial Sloan Kettering Cancer Center, and molecular profiling enabled by platforms from the Broad Institute. Staging and assessment incorporate imaging modalities standardized in guidelines from the National Comprehensive Cancer Network and functional imaging techniques refined at Peter MacCallum Cancer Centre.

Treatment

Therapeutic strategies are guided by subtype, stage, and patient factors and have been shaped by clinical trials conducted by cooperative groups such as the European Organisation for Research and Treatment of Cancer, National Cancer Institute, and the Children's Oncology Group. Core modalities include combination chemotherapy regimens pioneered in protocols from NCI and Dana‑Farber Cancer Institute, anti‑CD20 monoclonal antibody therapy developed through collaborations involving Genentech, targeted small molecules advanced by teams at Novartis and Roche, and radiotherapy techniques refined at MD Anderson. Hematopoietic stem cell transplantation performed at transplant centers like Fred Hutchinson Cancer Center is used for relapsed or high‑risk disease. Emerging approaches include CAR‑T cell therapies originating from research at University of Pennsylvania and immune checkpoint inhibitors evaluated in trials at Memorial Sloan Kettering Cancer Center.

Prognosis and epidemiology

Outcomes vary markedly by subtype, stage, and response to therapy; prognostic models such as those developed at International Prognostic Index consortia and refined in studies at M.D. Anderson Cancer Center assist risk stratification. Incidence and mortality patterns differ by region with data compiled by the World Health Organization, Global Burden of Disease Study, and national cancer registries including the Surveillance, Epidemiology, and End Results Program. Survival improvements over recent decades have been attributed to advances reported from centers like Stanford University and Dana‑Farber Cancer Institute and to treatments approved by regulators such as the U.S. Food and Drug Administration.

Category:Cancer